Cuiling Zhang

Cuiling Zhang

Auto-generated profile, based on publicly available information

Cuiling Zhang

Changchun Veterinary Research Institute Chinese Academy of Agricultural Sciences Changchun China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
CZCuiling Zhang
Cuiling Zhang
WRWeigang Ren
Weigang Ren
QLQingxin Liu
Qingxin Liu
ZTZhikai Tan
Zhikai Tan
JLJUNWEI LI
JUNWEI LI
CTChunyi Tong
Chunyi Tong
Introduction: In this study, we report on the development of an effective delivery system for siRNAs; a novel cell-penetrating peptide (CPP), T9(dR), obtained from transportan (TP), was used for in vivo and in vitro testing. Methods: In this study, toxicity of T9(dR) and TP and efficient delivery of siRNA were tested in 293T, MDCK, RAW, and A549 cells. Furthermore, T9(dR)- and TP-delivered siRNAs against nucleoprotein (NP) gene segment of influenza virus (siNP) were studied in both cell lines and mice. Results: Gel retardation showed that T9(dR) effectively condensed siRNA into nanoparticles sized between 350 and 550 nm when the mole ratio of T9(dR) to siRNA was ≥4:1. In vitro studies demonstrated that T9(dR) successfully delivered siRNA with low cellular toxicity into several cell lines. It was also observed that T9(dR)-delivered siRNAs inhibited replication of influenza virus more efficiently as compared to that delivered by TP into the MDCK and A549 cells. It was also noticed that when given a combined tail vein injection of siNP and T9(dR) or TP, all mice in the 50 nmol siNP group infected with PR8 influenza virus survived and showed weight recovery at 2 weeks post-infection. Conclusion: This study indicates that T9(dR) is a promising siRNA delivery tool with potential application for nucleotide drug delivery.

19 November 2024 in Journal of Virology
Verified
Journal Article
Open access
CZCuiling Zhang
Cuiling Zhang
QJQiwei Jiang
Qiwei Jiang
ZLZirui Liu
Zirui Liu
NLNan Li
Nan Li
ZHZhuo Hao
Zhuo Hao
YLYiquan Li
Yiquan Li
Autophagy is a cellular self-defense mechanism by which cells can kill invading pathogenic microorganisms and increase the presentation of components of pathogens as antigens. Contrarily, pathogens can utilize autophagy to enhance their own replication. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) NSP6 can interact with ATPase proton pump component to inhibit lysosomal acidification, which was implicated in the autophagy process. However, research on how SARS-CoV-2 NSP6 affected autophagy, and its impact on virus replication is still lacking. Coronavirus NSP6 has been reported to promote coronavirus replication by limiting autophagosome expansion. However, this finding has not been confirmed in coronavirus disease 2019 (COVID-19). We investigated the effect of NSP6 protein on autophagosomes in different mutant strains of SARS-CoV-2 and revealed that the size of autophagosomes was reduced by NSP6 of the wild-type and Delta variant of SARS-CoV-2. In addition, we found that SARS-CoV-2 NSP6 localized to the lysosome and had an inhibitory effect on the binding of autophagosomes to the lysosome, which blocked the autophagy flux; this may be related to endoplasmic reticulum (ER)-related pathways. We also found that sigma-1 receptor (SIGMAR1) knock out (KO) reversed NSP6-induced autophagosome abnormality and resisted SARS-CoV-2 infection, which responds to the fact that SIGMAR1 is likely to be used as a potential target for the treatment of SARS-CoV-2 infection. In summary, we have provided a preliminary explanation of the effects on autophagy of the SARS-CoV-2 NSP6 protein from the pre-autophagic and late stages, and also found that SIGMAR1 is likely to be used as a potential target for SARS-CoV-2 therapy to develop relevant drugs. IMPORTANCE: We have provided a preliminary explanation of the effects on autophagy of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) non-structure protein 6 from the pre-autophagic and late stages, and also found that sigma-1 receptor is likely to be used as a potential target for SARS-CoV-2 therapy to develop relevant drugs.

6 September 2026 in Advanced Science
Verified
Journal Article
Open access
HLHui Li
Hui Li
BZBohan Zhang
Bohan Zhang
CSChao Shang
Chao Shang
YLYi Li
Yi Li
TZTe Zhao
Te Zhao
ZLZhiping Li
Zhiping Li
The persistent evolution of SARS‐CoV‐2 and the concomitant risk of life‐threatening hyperinflammation, such as cytokine storm syndrome, underscore the urgent need for therapeutic strategies that simultaneously target viral replication and dysregulated host immunity. Herein, we describe a dual‐membrane biomimetic nanoplatform, designated [A&T]MLN, comprising siRNA‐loaded lipid nanoparticles with a hybrid membrane derived from ACE2‐overexpressing HEK293T cells and THP‐1 macrophages. This design integrates a high‐density viral decoy based on ACE2 with the inherent immunomodulatory capacity of macrophage membranes. [A&T]MLN demonstrates broad‐spectrum and potent neutralization of diverse SARS‐CoV‐2 variants by competitively blocking viral entry, while actively scavenging key inflammatory cytokines (including IL‐6, IL‐1β, and TNF‐α) via membrane‐displayed receptors. In a murine model of acute lung injury that recapitulates COVID‐19 immunopathology, [A&T]MLN treatment significantly attenuated pulmonary inflammation and tissue damage. Additionally, the platform enabled efficient cytosolic delivery of siRNA, establishing a third modality for intracellular suppression of viral gene expression. Collectively, [A&T]MLN represents a complementary triple‐modal therapy that simultaneously addresses viral entry, intracellular replication, and hyperinflammation (the core interconnected pathologies of severe COVID‐19), offering a versatile and adaptive strategy against evolving SARS‐CoV‐2 variants and related inflammatory syndromes.